

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Seladelpar for previously treated primary biliary cholangitis ID6429

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	<u>General</u>
Gilead Sciences (seladelpar)	 All Wales Therapeutics and Toxicology Centre
Patient/carer groups	 Allied Health Professionals Federation
 Addenbrookes Liver Transplant Association 	 Board of Community Health Councils in Wales
Black Health Agency	British National Formulary
British Liver Trust	Care Quality Commission
Gene People	Department of Health - Northern Ireland
Genetic Alliance UK	 Healthcare Improvement Scotland
GUTS UK	 Medicines and Healthcare products
Liver4Life	Regulatory Agency
M (1 12 0 (11117)	N. C. LA C. C. CD.
	•
	National Pharmacy AssociationNHS Confederation
PSC SupportSouth Asian Health Foundation	
	Scottish Medicines Consortium
Specialised Healthcare Alliance	Scottish Society of Gastroenterology
Hoolthoore professional groups	Welsh Government Walsh Haalth Considered Considered
Healthcare professional groups	Welsh Health Specialised Services Committee
 Association of Surgeons of Great Britain and Ireland 	Committee
British Association for the Study of the	Possible comparator companies
Liver	 AAH Pharmaceuticals (fenofibrate)
British Geriatrics Society	 Accord-UK (fenofibrate)
British Liver Nurses Forum	 ADVANZ Pharma (ursodeoxycholic
British Society of Gastroenterology	acid, Obeticholic acid)
British Transplantation Society	 Alliance Healthcare (Distribution)
NHS Blood and Transplant	(fenofibrate)
Primary Care Society for	 Dr. Falk Pharma UK (ursodeoxycholic
Gastroenterology	acid)
Royal College of Anaesthetists	 Galen (ursodeoxycholic acid)
Royal College of General Practitioners	 Genus Pharmaceuticals (fenofibrate)
Royal College of Nursing	 Glenmark Pharmaceuticals Europe
Royal College of Pathologists	(ursodeoxycholic acid)
Royal College of Physicians	 Ipsen (elafibranor)
Royal College of Surgeons	 Medihealth (Northern) (fenofibrate)
Royal Pharmaceutical Society	 Noumed Life Sciences (bezafibrate)

Provisional stakeholder list for the evaluation of seladelpar for previously treated primary biliary cirrhosis ID6429



Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
 Royal Society of Medicine UK Clinical Pharmacy Association Others Department of Health and Social Care NHS England 	 Phoenix Healthcare Distribution (fenofibrate) Sigma Pharmaceuticals (fenofibrate) Strides Pharma UK (ursodeoxycholic acid) Sun Pharma UK (fenofibrate) Teva UK (bezafibrate, fenofibrate) Torrent Pharma (fenofibrate) Viatris UK Healthcare (fenofibrate) Wockhardt UK (ursodeoxycholic acid)
	 Zentiva Pharma UK (fenofibrate) Relevant research groups Cochrane Hepato-Biliary Group Foundation for Liver Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of seladelpar for previously treated primary biliary cirrhosis ID6429





The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.